

# News Release

August 29, 2019  
EA Pharma Co., Ltd.

## EA Pharma Invests in a New Venture Capital Fund

EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Chuo-ku, Tokyo, Japan) (hereinafter “EA Pharma”) announced today that EA Pharma has entered in to an agreement to invest Remiges BioPharma Fund II, LP (hereinafter “Fund”), established by Remiges Ventures (President, Taro Inaba, offices in Tokyo, Boston and Seattle), up to 10 million dollars cumulatively.

As a gastrointestinal specialty pharma, EA Pharma is focused on “inflammatory bowel disease”, “liver and pancreatic diseases”, “gastrointestinal function and symptoms improvement”, “gastrointestinal mucosal protection” and “supports for gastrointestinal endoscopy/surgery” and aims to provide pharmaceuticals, medical devices and other solutions for the disease areas with high unmet medical needs.

EA Pharma expects to build up a strong network between the venture companies having early stage seeds in Japan, North America, Europe, Israel and other regions to bring innovations unique to EA Pharma. In addition, EA Pharma dispatches its employees to Regimes Ventures to cultivate global-level human resources having a keen sense for discovery.

EA Pharma aims to continually contribute to patients suffering from gastrointestinal diseases, their families and healthcare providers in the world.

### ■ About the Fund

Fund name	Remiges BioPharma Fund II, LP
Establishment	June 2019
Business offices	Tokyo Japan, Boston and Seattle USA
Fund size	Maximum 150 million dollars
Funding period	10 years
Funding area	Research seeds, early-stage drugs and medical devices
Funding regions	North America, Europe, Israel, Japan
URL	<a href="http://www.remigesventures.com">www.remigesventures.com</a>

End

[More Information](#)

■ **About EA Pharma Co., Ltd.**

EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year's history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, production & logistics and sales & marketing.

For more information on EA Pharma, please see <http://www.eapharma.co.jp/en/>

Media Inquiries:

Corporate Planning Dept., EA Pharma Co., Ltd.

TEL: +81-(0)3-6280-9802

email: [contact\\_ea@eapharma.co.jp](mailto:contact_ea@eapharma.co.jp)